Downregulation of 15-lipoxygenase 2 by glucocorticoid receptor in prostate cancer cells

International Journal of Oncology

Volumn 36, Issue 6, 2010, Pages 1541-1549

  Feng, Ying ^a   Bai, Xiangyang ^a   Yang, Qiuhui ^a   Wu, Hong ^a   Wang, Dian ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

15 lipoxygenase 2; Glucocorticoid receptor; Promoter; Prostate cancer

Indexed keywords

15 LIPOXYGENASE 2; DEXAMETHASONE; DNA FRAGMENT; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; LIPOXYGENASE; LUCIFERASE; MIFEPRISTONE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; LF1 GENE; LF2 GENE; LF3 GENE; LF4 GENE; LF5 GENE; LF6 GENE; LF7 GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; REPORTER GENE; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION INITIATION SITE;

ARACHIDONATE 15-LIPOXYGENASE; BLOTTING, WESTERN; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MUTAGENESIS, SITE-DIRECTED; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, GLUCOCORTICOID; RESPONSE ELEMENTS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 77951532119     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000641     Document Type: Article

References (32)

1. Brash AR, Boeglin WE and Chang MS: Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci USA 94: 6148-6152, 1997.
2. Shappell SB, Boeglin WE, Olson SJ, Kasper S and Brash AR: 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 155: 235-245, 1999. (Pubitemid 29318721)
3. Xu XC, Shappell SB, Liang Z, et al: Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 5: 121-127, 2003. (Pubitemid 36369007)
4. Wang D, Chen S, Feng Y, et al: Reduced expression of 15-lipoxygenase 2 in human head and neck carcinomas. Tumour Biol 27: 261-273, 2006. (Pubitemid 44260251)
5. Subbarayan V, Xu XC, Kim J, et al: Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7: 280-293, 2005. (Pubitemid 40411640)
6. Jack GS, Brash AR, Olson SJ, et al: Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 31: 1146-1154, 2000.
7. Tang S, Bhatia B, Maldonado CJ, et al: Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem 277: 16189-16201, 2002. (Pubitemid 34967907)
8. Bhatia B, Tang S, Yang P, et al: Cell-autonomous induction of functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) contributes to replicative senescence of human prostate progenitor cells. Oncogene 24: 3583-3595, 2005. (Pubitemid 40756228)
9. Tang S, Bhatia B, Zhou J, et al: Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells. Oncogene 23: 6942-6953, 2004. (Pubitemid 39279995)
10. Krieg P, Marks F and Furstenberger G: A gene cluster encoding human epidermis-type lipoxygenases at chromosome 17p13.1: cloning, physical mapping, and expression. Genomics 73: 323-330, 2001. (Pubitemid 32463728)
11. Ham J, Thomson A, Needham M, Webb P and Parker M: Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumour virus. Nucleic Acids Res 16: 5263-5276, 1988.
12. Beato M: Gene regulation by steroid hormones. Cell 56: 335-344, 1989.
13. Beato M, Chalepakis G, Schauer M and Slater EP: DNA regulatory elements for steroid hormones. J Steroid Biochem 32: 737-747, 1989.
14. Fakih M, Johnson CS and Trump DL: Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 60: 553-561, 2002. (Pubitemid 35246431)
15. Li Z, Chen Y, Cao D, et al: Glucocorticoid up-regulates transforming growth factor-beta (TGF-beta) type II receptor and enhances TGF-beta signaling in human prostate cancer PC-3 cells. Endocrinology 147: 5259-5267, 2006. (Pubitemid 44790581)
16. Yano A, Fujii Y, Iwai A, Kageyama Y and Kihara K: Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 12: 3003-3009, 2006. (Pubitemid 43837344)
17. Gao QZ, Lu JJ, Liu ZD, Zhang H, Wang SM and Xu H: Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression. Asian J Androl 10: 635-641, 2008. (Pubitemid 351865769)
18. Yemelyanov A, Czwornog J, Chebotaev D, et al: Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 26: 1885-1896, 2007.
19. Nishimura K, Nonomura N, Satoh E, et al: Potential mechanism for the effects of dexamethasone on growth of androgenindependent prostate cancer. J Natl Cancer Inst 93: 1739-1746, 2001. (Pubitemid 33130263)
20. Koufali MM, Moutsatsou P, Sekeris CE and Breen KC: The dynamic localization of the glucocorticoid receptor in rat C6 glioma cell mitochondria. Mol Cell Endocrinol 209: 51-60, 2003. (Pubitemid 37353082)
21. Felinski EA, Cox AE, Phillips BE and Antonetti DA: Glucocorticoids induce transactivation of tight junction genes occludin and claudin-5 in retinal endothelial cells via a novel cis-element. Exp Eye Res 86: 867-878, 2008.
22. Dondi D, Maggi R, Scaccianoce E, Martini L, Motta M and Poletti A: Expression and role of functional glucocorticoid receptors in the human androgen-independent prostate cancer cell line, DU145. J Mol Endocrinol 26: 185-191, 2001. (Pubitemid 32514609)
23. Onica T, Nichols K, Larin M, et al: Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter. Mol Pharmacol 73: 451-460, 2008. (Pubitemid 351159215)
24. Martindale RJ: The extra pharmacopoeia. 31st edition, UK: Royal Pharmaceutical Society, London, 1996.
25. Koutsilieris M, Mitsiades C, Dimopoulos T, et al: Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer. Expert Opin Investig Drugs 11: 283-293, 2002. (Pubitemid 34144871)
26. Beato M, Herrlich P and Schutz G: Steroid hormone receptors: many actors in search of a plot. Cell 83: 851-857, 1995. (Pubitemid 26006527)
27. Chebotaev D, Yemelyanov A, Zhu L, Lavker RM and Budunova I: The tumor suppressor effect of the glucocorticoid receptor in skin is mediated via its effect on follicular epithelial stem cells. Oncogene 26: 3060-3068, 2007. (Pubitemid 46733642)
28. De Bosscher K, Vanden Berghe W and Haegeman G: The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24: 488-522, 2003. (Pubitemid 37059110)
29. Necela BM and Cidlowski JA: Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc Am Thorac Soc 1: 239-246, 2004.
30. Fixemer T, Remberger K and Bonkhoff H: Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 54: 79-87, 2003. (Pubitemid 36120323)
31. Torlakovic E, Lilleby W, Berner A, et al: Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma. Int J Cancer 117: 381-386, 2005. (Pubitemid 41429561)
32. Mohler JL, Chen Y, Hamil K, et al: Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res 2: 889-895, 1996. (Pubitemid 26168942)